David Butler Email & Phone Number

Boston, Ma, Us

Boston, Massachusetts, United States

Hongene is a global specialist in nucleic acid raw material supply and CDMO services, committed to providing high-quality, high-value products with best-in-class lead times.Dedicated to the universal accessibility of nucleic therapies, we apply our world-renowned expertise and specialized capabilities to ensure your project is delivered on time, in full and on budget.As a trusted partner with decades of world class experience in the field, we provide end-to-end guidance along your journey to patients with a vertically integrated supply chain that supports you from small-scale synthesis to GMP manufacturing — all underpinned by consistently high purity, market-leading capacity and a commitment to innovation. We can grow together and realize the high potential of nucleic acids to bring life changing therapies to patients.

Preclinical stage gene therapy company using exosome delivered RNA therapies for tuneable control of gene expression to treat rare disease.

Boston, Massachusetts, United States

https://ventures.yale.edu/about/entrepreneurs-in-residence

Cambridge, Massachusetts, United States

• Leadership team member, establishing business strategy, issue resolution• Built a multi-tiered chemistry organization that including oligonucleotide synthesis, medicinal andcomputational chemistry, compound management, oligonucleotide analytics, outsourcing,and CMC• Early Program Team lead for Alpha-1 Antitrypsin. Established a screening funnel paradigm forLead Discovery• Founder and leader of the Oligonucleotide Design Team, matrixed across Discovery todrive the advancement of oligonucleotide chemistry and design processes• Established a global network of small molecule and oligonucleotide suppliers to support Discovery and Development

Cambridge, Massachusetts, United States

• Member of leadership team during progression from ‘NewCo’ to ‘GrowthCo’. Developed earlybusiness strategy including mission, vision and goals• Inventor of early technology advancements

Cambridge, Massachusetts, United States

• Advanced Wave’s regulatory control strategy for API stereochemistry• Interfaced with health agencies regarding CMC through type B, C, and Scientific Advice meetings• Oversaw a global network of CMO/CROs• Developed strategic partnerships to build innovative, scalable, and cost‐effective manufacturingsolutions• Participated in cross‐functional teams driving discovery pipeline into development

• Oversaw design and construction of lab supporting chemistry discovery, and annual in‐housemanufacture of up to 100 kg of stereodefined phosphoramidites• Led scale‐up, supply chain continuity and regulatory control strategy for API starting materialsincluding CPG support and a portfolio of 40 stereodefined phosphoramidites• Created a forecast system for stereodefined RSM and API manufacture• Established strategic partnerships with CMO/CROs, conducted technical audits• 2016 CREST award winner (awarded annually to one outstanding employee at Wave)

Ontorii and Chiralgen joined together to form Wave Life Sciences• Joint inventor of foundational Wave compositions IP• Synthesis of chiral amidite building blocks, oligonucleotides and oligonucleotide prodrugs• Joint inventor of the SOSIC method for mixed backbone stereodefined phosphorothioateoligonucleotides• Designed first experiments exploring the impact of phosphorothioate stereochemistry onoligonucleotide pharmacology in vivo (Nature Biotechnology, 2017)

• Synthesis of building blocks – Lipids, phosphoramidites, ligands, linkers, solid supports, peptides,formulations• Project lead or core team member on multiple siRNA discovery teams• Supervised laboratory expansion, lab safety and chemical inventory management• Co‐leader of academic R&D collaboration with MPI‐CBG, Dresden• Managed activities of 6 chemists at an Indian CRO to support internal platform development

Woburn, Massachusetts, United States

Contract Research and Custom Synthesis.• Multi‐step synthesis of more than 400 unique final compounds at mg to kg scale for customersacross pharmaceutical and chemical industries• Joint inventor of a new class of monoamine re‐uptake inhibitors (pyrovalerones) for potentialcocaine addiction therapy and treatment of Parkinson’s disease. NIH supported.• All work met pre‐established deadlines and purity specifications with zero failure• Solved an extremely difficult chemistry problem for a pharmaceutical partner, enabling synthesis of 60triazolopyridine antibacterials, named joint inventor on patent• Synthesis and isolation of 120 compounds within 6 months for biotech partner, explored astreatment for parasitic animal disease

London, England, United Kingdom

Postdoctoral Fellowship supported by the Engineering and Physical Sciences Research Council (EPSRC).• Investigated molecular gears as components for nanoscale systems• Developed asymmetric organometallic catalysts as chiral DMAP analogs

Relocated to Queen Mary, University of London

Ottawa, Ontario, Canada

Postdoctoral Fellowship supported by the Natural Sciences and Engineering Research Council (NSERC) and the Environmental Science and Technology Alliance of Canada (ESTAC).• Achieved phosgene‐free, ‘green’ route to industrially important isocyanates• Explored palladium catalyzed ring‐opening of aziridines and azetidines with heterocumulenes togive biologically relevant heterocycles

Phd, Chemistry

PhD program sponsored by Johnson Matthey. PhD Thesis Title: Catalytic Carbonylation of Ammonia to Urea

Bsc, Chemistry